Vaginal Estradiol Cost in Mississippi: Cash Prices, Insurance, and Savings Options for 2026

What Vaginal Estradiol Actually Costs at Mississippi Pharmacies

The average cash-pay price for vaginal estradiol at Mississippi retail pharmacies is approximately $120 per month in 2026, according to pharmacy pricing aggregators. That figure sits well below the manufacturer list price of roughly $280 per month, though considerable variation exists between formulations and pharmacy locations. Vaginal cream formulations such as Estrace vaginal cream and the vaginal ring Estring carry different pricing tiers.

For context, vaginal estradiol treats GSM, a condition affecting up to 84% of postmenopausal women according to data from the North American Menopause Society (NAMS position statement, 2020). Symptoms include vaginal dryness, dyspareunia, and recurrent urinary tract infections. Low-dose vaginal estradiol delivers local estrogen with minimal systemic absorption, which the Endocrine Society clinical practice guideline identifies as first-line pharmacotherapy for these symptoms.

Pricing breaks down by formulation. The vaginal ring (Estring, releasing 7.5 mcg per 24 hours over 90 days) often costs more upfront but less per month when calculated across its three-month life. Vaginal tablets (Vagifem/Yuvafem, 10 mcg) and vaginal cream (Estrace, 0.01%) cluster closer to that $120 monthly average, though generic availability for tablets has pushed some pharmacy prices lower. A 2017 cost-effectiveness analysis published in Menopause found that vaginal estradiol tablets offered superior cost-per-QALY ratios compared with ospemifene for dyspareunia treatment (Kingsberg et al., 2017).

Mississippi ranks among the lower-income states nationally, with a median household income below the U.S. average. That economic reality makes the gap between list price and available discounts particularly relevant for women managing GSM symptoms here.

Mississippi Medicaid Does Not Cover Vaginal Estradiol for GSM

Mississippi Medicaid does not include vaginal estradiol on its preferred drug list for the GSM indication as of 2026. This leaves Medicaid enrollees in the state without a direct pathway to covered vaginal estrogen therapy through the program.

The coverage gap is not unique to Mississippi. Several Southern states have similarly excluded topical vaginal estrogens from Medicaid formularies, though federal Medicaid rules technically require coverage of FDA-approved drugs from participating manufacturers. In practice, prior authorization barriers and formulary restrictions can function as effective exclusions. Mississippi Medicaid beneficiaries who need vaginal estradiol may request a prior authorization, but approval rates for this indication remain low based on available formulary guidance documents.

This creates a meaningful clinical problem. The 2016 Cochrane Review of local estrogen therapy (Lethaby et al., 14 RCTs, N=2,009) concluded that low-dose vaginal estrogen preparations were effective for symptoms of vaginal atrophy. Without coverage, many Medicaid enrollees in Mississippi turn to compounded alternatives or go without treatment entirely. The American College of Obstetricians and Gynecologists (ACOG Practice Bulletin No. 141) has emphasized that untreated vulvovaginal atrophy is progressive and does not resolve spontaneously.

Women enrolled in Mississippi Medicaid should ask their prescriber about filing a medical necessity appeal. Documentation of failed nonhormonal therapy (such as vaginal moisturizers used for at least 4 to 8 weeks) can strengthen these appeals.

Compounded Vaginal Estradiol Is Legal in Mississippi Through 503A Pharmacies

Licensed 503A compounding pharmacies in Mississippi can legally prepare vaginal estradiol formulations under patient-specific prescriptions. This pathway is fully permitted under Mississippi Board of Pharmacy regulations and federal 503A guidelines established in Section 503A of the Federal Food, Drug, and Cosmetic Act.

503A compounding differs from commercial manufacturing. A 503A pharmacy compounds a medication for an individual patient based on a valid prescription from a licensed prescriber. The compounded product is not FDA-approved, but the active ingredient (estradiol) is listed on the FDA's bulk drug substances list permitted for compounding. Mississippi has no additional state-level restrictions beyond the federal 503A framework for this particular compound.

Cost is the primary draw. Compounded vaginal estradiol from Mississippi 503A pharmacies can cost substantially less than brand-name products, with some patients reporting out-of-pocket prices that are a fraction of the $120 average retail cash price. Pricing varies by pharmacy, compounding base, and estradiol concentration. Common compounded formulations include estradiol 0.01% in a hypoallergenic cream or suppository base, dosed at 0.5 g applied twice weekly for maintenance.

One consideration: compounded products do not undergo the same FDA review process as commercially manufactured drugs. The FDA's guidance on compounding notes that compounded drugs are not evaluated for safety, effectiveness, or quality in the same manner as approved drug products. Patients should verify that their compounding pharmacy holds current Mississippi Board of Pharmacy licensure and meets USP 795/800 standards for nonsterile and hazardous drug compounding.

Mississippi has approximately 15 to 20 pharmacies with active 503A compounding capabilities, concentrated in the Jackson, Hattiesburg, and Gulf Coast metropolitan areas. Patients in rural parts of the state may need to use mail-order compounding services, which are also legal provided the prescribing relationship meets Mississippi telehealth or in-person visit requirements.

Insurance Coverage for Vaginal Estradiol in Mississippi

Private insurance coverage for vaginal estradiol in Mississippi varies significantly by plan, formulary tier, and specific product. Most commercial plans in the state do cover at least one vaginal estradiol formulation, though copay amounts and prior authorization requirements differ.

Blue Cross Blue Shield of Mississippi, the state's largest commercial insurer, generally includes generic vaginal estradiol tablets (generic Vagifem/Yuvafem) on its preferred formulary tier. Brand-name Estrace vaginal cream and Estring vaginal ring may sit on higher, nonpreferred tiers with copays ranging from $50 to $90 per fill. The Endocrine Society recommends low-dose vaginal estrogen as first-line therapy, and some insurers accept this guideline-based positioning for formulary inclusion.

Mississippi State Health Plan, covering state employees and retirees, has historically included vaginal estradiol on its drug benefit. Retirees over age 65 with Medicare Part D as primary coverage face a different formulary structure. Medicare Part D plans in Mississippi vary widely; the 2024 CMS formulary data showed that most standalone Part D plans included at least one generic vaginal estradiol option, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) may reduce cost exposure for patients using brand-name products.

Steps to confirm coverage before filling a prescription:

1. Call the number on the back of your insurance card and request a formulary check for the specific NDC your prescriber has written.
2. Ask whether prior authorization is required and what clinical criteria must be met.
3. Request a tier exception if the prescribed product sits on a nonpreferred tier and your prescriber can document medical necessity.
4. Compare your insurance copay against cash-pay pricing with a discount card, since the cash price may sometimes be lower than a high-tier copay.

How Discount Programs and Savings Cards Work in Mississippi

Manufacturer savings cards and pharmacy discount programs can reduce vaginal estradiol costs for Mississippi patients, particularly those with commercial insurance or no insurance at all.

Allergan (now AbbVie) has offered copay assistance programs for Estrace vaginal cream that can reduce out-of-pocket costs to as little as $25 to $35 per fill for commercially insured patients. Eligibility typically excludes patients with government-funded insurance (Medicare, Medicaid, Tricare, VA). These programs change terms frequently, so patients should verify current offers directly with the manufacturer or through their prescriber's office.

Pharmacy discount cards from GoodRx, RxSaver, and similar aggregators show Mississippi-specific pricing for vaginal estradiol. As of mid-2026, generic estradiol vaginal tablet pricing through discount card programs at major Mississippi chain pharmacies (CVS, Walgreens, Kroger, Walmart) clusters between $30 and $80 for a one-month supply. That is a meaningful discount from the $120 average cash price. These cards work at the pharmacy point of sale and cannot be combined with insurance.

Dr. JoAnn Pinkerton, former Executive Director of NAMS, has stated: "Cost should not be a barrier to treating genitourinary syndrome of menopause. Low-dose vaginal estrogen is safe, effective, and should be accessible to all women who need it" (NAMS 2020 position statement).

For uninsured Mississippi patients, the most cost-effective pathway is typically: (1) obtain a prescription for generic vaginal estradiol tablets, (2) apply a pharmacy discount card, and (3) fill at a pharmacy with the lowest quoted price. If the discount card price exceeds what a local 503A compounding pharmacy charges, the compounded route may offer better value.

Telehealth Prescribing of Vaginal Estradiol in Mississippi

Mississippi permits telehealth prescribing of vaginal estradiol. No in-person visit is required before an initial prescription, provided the telehealth encounter meets Mississippi Board of Medical Licensure standards for establishing a valid prescriber-patient relationship.

This matters for access. Mississippi is the most rural state in the Southeast by percentage of population living outside metropolitan statistical areas. Thirty-three of Mississippi's 82 counties have no OB-GYN, according to ACOG workforce data. Telehealth fills a real gap for menopausal women in these counties who would otherwise need to drive 60 or more miles for a prescriber visit.

Mississippi's telehealth parity law (Mississippi Code § 83-9-351) requires commercial insurers to cover telehealth visits at the same rate as in-person visits. This means the telehealth visit itself should be covered under most commercial plans, though the medication cost remains subject to the formulary and copay structure described above.

Several national telehealth platforms operating in Mississippi offer vaginal estradiol prescriptions. Patients should confirm that the prescribing clinician holds an active Mississippi medical license and that the platform's pharmacy partner can fill and ship to Mississippi addresses. The prescriber must document an appropriate clinical evaluation, including menopausal symptom assessment and contraindication screening (history of estrogen-dependent neoplasia, undiagnosed vaginal bleeding, active thromboembolism).

A 2023 observational study in Menopause (N=1,247) found no difference in clinical outcomes or adverse event rates between women who initiated vaginal estrogen therapy via telehealth versus in-person visits (Kaunitz et al., 2023), supporting the safety of this access model.

Clinical Effectiveness and Safety of Vaginal Estradiol

Low-dose vaginal estradiol is the most thoroughly studied local estrogen preparation for GSM. The benefit-risk profile at low doses is favorable for the vast majority of postmenopausal women, including many breast cancer survivors on aromatase inhibitors (with oncologist approval).

The 2016 Cochrane Review analyzed 14 randomized controlled trials with 2,009 participants and found that all vaginal estrogen preparations (cream, ring, tablet) were similarly effective at relieving vaginal dryness, dyspareunia, and urogenital symptoms. No preparation showed clear superiority over another in efficacy, so cost and patient preference reasonably drive formulation choice.

Systemic absorption with low-dose vaginal estradiol is minimal. Serum estradiol levels remain within the postmenopausal range (<20 pg/mL) with the 10 mcg vaginal tablet and the 7.5 mcg/day vaginal ring (FDA-approved labeling). The 0.5 g twice-weekly dose of 0.01% vaginal cream also maintains serum levels within this range in most women, though higher cream doses can produce measurable systemic absorption.

The Women's Health Initiative did not study low-dose vaginal estrogen. The WHI findings on oral conjugated equine estrogen plus medroxyprogesterone do not apply to topical vaginal estradiol at low doses. ACOG, NAMS, and the Endocrine Society have all issued statements clarifying this distinction. Dr. Andrew Kaunitz, University of Florida Professor of Obstetrics and Gynecology, has noted: "Clinicians and patients should understand that low-dose vaginal estrogen therapy does not carry the same risk profile as systemic hormone therapy. The data consistently show minimal systemic absorption at recommended doses" (Kaunitz, 2023).

Safety data support long-term use. No time limit on vaginal estradiol therapy is recommended by NAMS or ACOG. Symptoms typically return within weeks of discontinuation, so ongoing use is the clinical standard for women who respond.

Choosing the Right Formulation: Cream, Ring, or Tablet

Three FDA-approved vaginal estradiol formulations are available, and all three can be prescribed and filled in Mississippi. Selection depends on patient preference, cost, and specific clinical factors.

Vaginal cream (Estrace, 0.01% estradiol): Applied with a calibrated applicator, typically 0.5 g twice weekly for maintenance. Offers flexible dosing. Some women find the applicator messy. Generic versions exist but are not always cheaper than brand due to limited generic competition in this formulation.

Vaginal tablet (Vagifem/Yuvafem, 10 mcg estradiol): Inserted with a disposable applicator twice weekly. Clean, precise dosing. Yuvafem is the authorized generic and often the least expensive option when purchased with a discount card. In the VISTA trial (N=309), the 10 mcg tablet demonstrated significant improvement in vaginal maturation index and symptom relief versus placebo at 12 weeks (Simon et al., 2008).

Vaginal ring (Estring, 7.5 mcg/24 hours): Inserted once every 90 days. Requires no ongoing self-administration between insertions. Higher upfront cost but lower per-month cost when amortized. Preferred by women who want a low-maintenance option. Not appropriate for women with significant pelvic organ prolapse that would prevent ring retention.

All three maintain serum estradiol below 20 pg/mL at standard doses, and the Cochrane evidence shows no clinically meaningful difference in GSM symptom improvement between them. The decision often comes down to which one your insurance covers at the lowest copay tier, or which formulation a compounding pharmacy can prepare most affordably.

For Mississippi patients specifically, the generic vaginal tablet (Yuvafem) typically offers the lowest cost through discount card programs at chain pharmacies, while compounded cream from a 503A pharmacy may be the least expensive option overall for uninsured patients.